Foghorn Therapeutics Inc.

NASDAQ:FHTXUnited States

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.

Contact Information

Headquarters

500 Technology Square, Suite 700CAMBRIDGE, MA, United States 02139

Phone

617-586-3100

Fax

302-655-5049

Executives

President, Chief Executive Officer, Director

Adrian Gottschalk

Chief Financial Officer

Kristian Humer

Chief People Officer

Carlos Costa

Chief Scientific Officer

Steven Bellon

Chief Strategy and Business Operations Officer

Fanny Cavalie